Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  A. Vekhoff,et al.  A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial) , 2021, Blood.

[3]  F. Carrat,et al.  Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients * , 2021, The British journal of dermatology.

[4]  E. Clappier,et al.  UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome. , 2021, JAMA dermatology.

[5]  E. Clappier,et al.  Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease , 2021, Leukemia.

[6]  T. D. de Gruijl,et al.  Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes , 2021, Haematologica.

[7]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[8]  A. List,et al.  The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. , 2019, Blood.

[9]  P. Fenaux,et al.  Autoimmune manifestations associated with myelodysplastic syndromes , 2018, Annals of Hematology.

[10]  T. D. de Gruijl,et al.  Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes , 2018, Front. Immunol..

[11]  A. Enk,et al.  Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. , 2018, JCI insight.

[12]  H. Bontkes,et al.  Transcriptional profiling reveals functional dichotomy between human slan+ non‐classical monocytes and myeloid dendritic cells , 2017, Journal of leukocyte biology.

[13]  Renan Valieris,et al.  Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs , 2016, The Journal of experimental medicine.

[14]  M. Cazzola,et al.  Time-dependent changes in mortality and transformation risk in MDS. , 2016, Blood.

[15]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[16]  Ø. Bruserud,et al.  Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome , 2015, Oncoimmunology.

[17]  A. Danek,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS slan-de fi ned subsets of CD 16-positive monocytes : impact of granulomatous in fl ammation and M-CSF receptor mutation , 2015 .

[18]  Michael Poidinger,et al.  Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow , 2015, Nature Immunology.

[19]  M. Nussenzweig,et al.  Circulating precursors of human CD1c+ and CD141+ dendritic cells , 2015, The Journal of experimental medicine.

[20]  P. Fenaux,et al.  Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? , 2013, Best practice & research. Clinical haematology.

[21]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[22]  Peter Winter,et al.  SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. , 2011, Blood.

[23]  Wing-Cheong Wong,et al.  Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. , 2011, Blood.

[24]  I. Kotsianidis,et al.  Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. , 2011, Clinical immunology.

[25]  S. Pedreiro,et al.  Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus , 2012, Rheumatology International.

[26]  Silvano Sozzani,et al.  Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.

[27]  J. Casanova,et al.  Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors , 2010, Immunity.

[28]  P. Grossmann,et al.  Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function , 2009, Annals of the rheumatic diseases.

[29]  J. Casanova,et al.  Human CD 14 dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR 7 and TLR 8 Receptors , 2010 .

[30]  G. Mufti,et al.  IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome , 2009, British journal of haematology.

[31]  D. Margaritis,et al.  Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS) , 2009, Leukemia.

[32]  Lingyun Sun,et al.  Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression , 2008, Lupus.

[33]  F. Dammacco,et al.  Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. , 2008, Arthritis and rheumatism.

[34]  L. Gesualdo,et al.  Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. , 2008, Molecular immunology.

[35]  Eric Vivier,et al.  Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling , 2008, Genome Biology.

[36]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[37]  K. Schäkel,et al.  Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. , 2006, Immunity.

[38]  K. Migita,et al.  Reduced blood BDCA‐2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus , 2005, Clinical and experimental immunology.

[39]  P. Smolewski,et al.  Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus. , 2004, Mediators of Inflammation.

[40]  K. MacDonald,et al.  Characterization of human blood dendritic cell subsets. , 2002, Blood.

[41]  V. Pascual,et al.  Blood dendritic cells and DC-poietins in systemic lupus erythematosus. , 2002, Human immunology.

[42]  K. Schäkel,et al.  6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. , 2002, Immunity.

[43]  J. Smolen,et al.  Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. , 2001, Arthritis and rheumatism.

[44]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[45]  K. Schäkel,et al.  A novel dendritic cell population in human blood: one‐step immunomagnetic isolation by a specific mAb (M‐DC8) and in vitro priming of cytotoxic T lymphocytes , 1998, European journal of immunology.